Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMAHA-015 basket study of opevesostat in selected solid tumors
2024-519563-18-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label trial of opevesostat in breast cancer, ovarian cancer, fallopian tube cancer (PFTC) and 2 more (3 cohorts), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Planned start Sep 2025; status: authorised.
02
Drugs
opevesostat
03
Conditions
breast cancerovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)
Beyond the preview
Go deeper on 2024-519563-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519563-18-00.